Efficacy and safety of sequential use of everolimus in patients with metastatic renal cell carcinoma previously treated by bevacizumab with or without interferon therapy: Results from pooled analysis of AVATOR, CHANGE, and TRAIN studies.

Authors

Antoine Thiery- Vuillemin

Medical Oncology Unit, CHU Minjoz, Besançon, France

Antoine Thiery- Vuillemin , Aline Guillot , Thomas Steiner , Edwin Herrmann , Konstantinos N. Syrigos , Nadia Kelkouli , Agnese Cattaneo , Thierry Nguyen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 Genitourinary Cancers Symposium

bookmark_border

Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.

First Author: Peter J. Goebell

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

First Author: Martin Boegemann

insert_chart_outlined

Poster

2012 Genitourinary Cancers Symposium

bookmark_border

Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).

First Author: Jiahuai Tan

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).

First Author: B. Melichar